Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists
Joost Boeckmans, Alessandra Natale, Matthias Rombaut, Karolien Buyl, Brent Cami, Veerle De Boe, Anja Heymans, Vera Rogiers, Joery De Kock, Tamara Vanhaecke, Robim M. Rodrigues
Topics & Concepts
PioglitazoneSteatohepatitisPeroxisome proliferator-activated receptorHepatic stellate cellPharmacologyIn vitroFatty liverFenofibrateReceptorChemokineBiologyCancer researchChemistryEndocrinologyInternal medicineMedicineBiochemistryDiseaseDiabetes mellitusType 2 diabetesLiver Disease Diagnosis and TreatmentPeroxisome Proliferator-Activated ReceptorsLiver Diseases and Immunity